Abstract
Lutetium-177 coupled with a ligand for Prostate Specific Membrane Antigen ([177Lu]Lu-PSMA) is a new treatment in The Netherlands. Patients with metastasized castration resistant prostate carcinoma and progressive disease after hormonal therapy and chemotherapy, and no other regular therapeutic options, can be referred. A good clinical performance state, adequate bone marrow function and a PSMA PET/CT showing adequate targeting in all metastases are essential. The therapy consists of four to six intravenous administrations of 7.4 GBq [177Lu]Lu-PSMA, six weeks apart. Side effects are mild and consist of xerostomia, fatigue and bone marrow depression. This therapy is currently administered only in a few hospitals in The Netherlands, mainly in research setting. An EMA registered product is expected at the end of 2022, which can contribute to better availability for reimbursed treatment.
| Translated title of the contribution | Lutetium-177-PSMA in metastasized prostate carcinoma |
|---|---|
| Original language | Dutch |
| Article number | d6981 |
| Journal | Nederlands Tijdschrift voor Geneeskunde |
| Volume | 166 |
| Publication status | Published - 16 Mar 2023 |
Keywords
- Male
- Humans
- Positron Emission Tomography Computed Tomography
- Prostate/pathology
- Prostate-Specific Antigen
- Dipeptides/adverse effects
- Prostatic Neoplasms, Castration-Resistant/drug therapy
- Treatment Outcome
- Radiopharmaceuticals/adverse effects